Ablation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
Authors:
- Luigi Di BiaseLBLuigi Di Biase
- Kalyanam ShivkumarKSKalyanam Shivkumar
- Prasant MohantyPMPrasant Mohanty
- Roderick TungRTRoderick Tung
- Pasquale SantangeliPSPasquale Santangeli
- Luis Carlos SaenzLSLuis Carlos Saenz
- Miguel VaccaMVMiguel Vacca
- Atul VermaAVAtul Verma
- Yariv KhaykinYKYariv Khaykin
- Sanghamitra MohantySMSanghamitra Mohanty
- J. David BurkhardtJBJ. David Burkhardt
- 1 August 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 4 (4) , 478-485
Abstract
Background—: In patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy, freedom from ventricular arrhythmias (VAs) after endocardial ablation is limited. We compared the long-term freedom from recurrent VAs by using endocardial-alone ablation versus endo-epicardial substrate-based ablation. Methods and Results—: Forty-nine patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing ablation of ventricular tachycardia (VT) were divided into 2 groups: endocardial-alone ablation (group 1, n=23) and endo-epicardial ablation (group 2, n=26). All patients had an implantable cardioverter-defibrillator (ICD). Conventional and 3D mappings were used to determine the mechanism of induced VTs and to identify area of “scar” or “abnormal” myocardium. All critical sites responsible for VTs and points with “abnormal” potential were targeted for ablation from endocardium (group 1) or from both endocardium and epicardium (group 2). The procedural end point was noninducibility of sustained, monomorphic VT with isoproterenol. The presence of frequent premature ventricular contractions at the end of ablation was recorded. Patients were followed up by ECG, Holter, and ICD interrogation. After a follow-up of at least 3 years, freedom from VAs or ICD therapy was 52.2% (12/23) in group 1 and 84.6% (22/26) in group 2 ( P =0.029), with 21.7% (5/23) and 69.2% (18/26) patients off antiarrhythmic drugs ( P P <0.001]. Conclusions—: An endo-epicardial–based ablation strategy achieves higher long-term freedom from recurrent VAs off antiarrhythmic therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy when compared with endocardial-alone ablation. The presence of ≥10 premature ventricular contractions per minute after ablation is associated with more VA recurrence.Keywords
This publication has 28 references indexed in Scilit:
- Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/DysplasiaCirculation, 2010
- Ablation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular DysplasiaJournal of Cardiovascular Electrophysiology, 2010
- The influence of fat thickness on the human epicardial bipolar electrogram characteristics: measurements on patients undergoing open-heart surgeryEP Europace, 2009
- Epicardial Macro‐Reentrant Ventricular Tachycardia Exhibiting an Endocardial Centrifugal Activation Pattern in a Case with Arrhythmogenic Right Ventricular CardiomyopathyJournal of Cardiovascular Electrophysiology, 2009
- Arrhythmogenic right ventricular cardiomyopathy/dysplasiaOrphanet Journal of Rare Diseases, 2007
- A novel treatment strategy for therapy refractory ventricular arrhythmias in the setting of arrhythmogenic right ventricular dysplasiaEP Europace, 2007
- Catheter Ablation of Stable and Unstable Ventricular Tachycardias in Patients with Arrhythmogenic Right Ventricular DysplasiaJournal of Cardiovascular Electrophysiology, 2006
- Short- and Long-Term Success of Substrate-Based Mapping and Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular DysplasiaCirculation, 2005
- Right Ventricular Cardiomyopathy and Sudden Death in Young PeopleNew England Journal of Medicine, 1988
- Right ventricular dysplasia: a report of 24 adult cases.Circulation, 1982